BioXcel Therapeutics (BTAI) Common Equity (2022 - 2025)
Historic Common Equity for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$88.9 million.
- BioXcel Therapeutics' Common Equity fell 383.73% to -$88.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.9 million, marking a year-over-year decrease of 383.73%. This contributed to the annual value of -$93.1 million for FY2024, which is 6475.72% down from last year.
- BioXcel Therapeutics' Common Equity amounted to -$88.9 million in Q3 2025, which was down 383.73% from -$107.7 million recorded in Q2 2025.
- BioXcel Therapeutics' 5-year Common Equity high stood at $194.0 million for Q1 2022, and its period low was -$107.7 million during Q2 2025.
- Its 4-year average for Common Equity is -$5.9 million, with a median of -$56.5 million in 2023.
- As far as peak fluctuations go, BioXcel Therapeutics' Common Equity plummeted by 136707.03% in 2024, and later crashed by 383.73% in 2025.
- Over the past 4 years, BioXcel Therapeutics' Common Equity (Quarter) stood at $76.8 million in 2022, then crashed by 173.6% to -$56.5 million in 2023, then tumbled by 64.76% to -$93.1 million in 2024, then increased by 4.49% to -$88.9 million in 2025.
- Its Common Equity was -$88.9 million in Q3 2025, compared to -$107.7 million in Q2 2025 and -$90.2 million in Q1 2025.